Related Experiment Video
Updated: Apr 17, 2026
08:17
Reducing State Anxiety Using Working Memory Maintenance
Published on: July 19, 2017
8.3K
Managing anxiety associated with neurodegenerative disorders
1Department of Psychiatry, University of Illinois at Chicago 912 South Wood Street, Chicago, IL, 60612 USA.
F1000Prime Reports
|February 24, 2015
Summary
Anxiety is common in neurodegenerative disorders and cognitive impairment, worsening patient outcomes. This review covers anxiety
Area of Science:
- Neurology
- Psychiatry
Background:
- Anxiety is a frequent symptom in patients experiencing cognitive impairment.
- Anxiety correlates with poorer health outcomes in these patients.
- Limited research exists on anxiety specifically within neurodegenerative disorders.
Purpose of the Study:
- To discuss the prevalence and causes of anxiety in neurodegenerative disorders and cognitive impairment.
- To review current evaluation and treatment methods for anxiety in this population.
- To highlight evidence-based treatments and discuss research challenges.
Main Methods:
- Literature review of existing research on anxiety in neurodegenerative disorders.
- Analysis of etiological factors contributing to anxiety.
- Evaluation of current diagnostic and therapeutic strategies.
Main Results:
- Anxiety is prevalent and linked to negative outcomes in neurodegenerative conditions.
- Various factors contribute to the etiology of anxiety in this population.
- Current treatment options show variable efficacy and face research limitations.
Conclusions:
- Further research is needed to understand and effectively treat anxiety in neurodegenerative disorders.
- Addressing anxiety is crucial for improving patient outcomes.
- Challenges in studying and treating anxiety in this population require innovative approaches.
Related Concept Videos
01:26Anxiolytic Drugs: Overview
1.5K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.5K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:18Anxiety: Overview
1.3K
Anxiety is a common mental disorder featuring excessive worry, fear, and apprehension, significantly affecting daily life. People with anxiety disorders experience persistent and intense anxiety, interrupting their everyday functioning.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
1.3K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:15Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
01:30Generalized Anxiety Disorder
1.2K
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
1.2K